# Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer

> **NCT03051906** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Azienda Ospedaliero-Universitaria Careggi** · enrollment: 69 (estimated)

## Conditions studied

- Head and Neck Neoplasms

## Interventions

- **BIOLOGICAL:** Durvalumab
- **BIOLOGICAL:** Cetuximab
- **RADIATION:** Intensity modulated radiation therapy (IMRT)

## Key facts

- **NCT ID:** NCT03051906
- **Lead sponsor:** Azienda Ospedaliero-Universitaria Careggi
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01
- **Primary completion:** 2022-01
- **Final completion:** 2025-01
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2017-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03051906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03051906, "Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03051906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*